BR112017027350A2 - método para aumentar a solubilidade de estilbenoide, solução aquosa e seu uso e uso de alfa-glucano de redução - Google Patents
método para aumentar a solubilidade de estilbenoide, solução aquosa e seu uso e uso de alfa-glucano de reduçãoInfo
- Publication number
- BR112017027350A2 BR112017027350A2 BR112017027350A BR112017027350A BR112017027350A2 BR 112017027350 A2 BR112017027350 A2 BR 112017027350A2 BR 112017027350 A BR112017027350 A BR 112017027350A BR 112017027350 A BR112017027350 A BR 112017027350A BR 112017027350 A2 BR112017027350 A2 BR 112017027350A2
- Authority
- BR
- Brazil
- Prior art keywords
- stilbenoid
- solubility
- increasing
- aqueous solution
- alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
trata-se de uma solução aquosa que compreende, em estado dissolvido, - pelo menos um estilbenoide - pelo menos um sacarídeo, e um método para aumentar a solubilidade de um estilbenoide em água.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15177541.8 | 2015-07-20 | ||
EP15177541.8A EP3120838A1 (en) | 2015-07-20 | 2015-07-20 | Aqueous solution comprising a polyphenol |
PCT/EP2016/067188 WO2017013121A1 (en) | 2015-07-20 | 2016-07-19 | Aqueous solution comprising a stilbenoid |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112017027350A2 true BR112017027350A2 (pt) | 2018-08-28 |
BR112017027350B1 BR112017027350B1 (pt) | 2023-08-01 |
Family
ID=
Also Published As
Publication number | Publication date |
---|---|
PL3324935T3 (pl) | 2023-04-24 |
JP2018521088A (ja) | 2018-08-02 |
CN108601729A (zh) | 2018-09-28 |
CN108601729B (zh) | 2022-10-25 |
HK1254524A1 (zh) | 2019-07-19 |
JP6505310B2 (ja) | 2019-04-24 |
EP3324935A1 (en) | 2018-05-30 |
WO2017013121A1 (en) | 2017-01-26 |
PT3324935T (pt) | 2022-11-04 |
RS63867B1 (sr) | 2023-01-31 |
EP3324935B1 (en) | 2022-10-19 |
US11185514B2 (en) | 2021-11-30 |
US20200108026A1 (en) | 2020-04-09 |
DK3324935T3 (da) | 2022-11-28 |
ES2929527T3 (es) | 2022-11-29 |
EP3120838A1 (en) | 2017-01-25 |
US20180214387A1 (en) | 2018-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017011535A2 (es) | Composiciones de ácido obeticólico y métodos de uso | |
CL2017002401A1 (es) | Anticuerpos contra icos | |
CL2016001694A1 (es) | Un panel para mobiliario | |
CL2017002422A1 (es) | Derivados de maitansinoide, conjugados de los mismos, y métodos de uso. | |
CL2016002679A1 (es) | Métodos para mejorar o acelerar la recuperación física después la cirugía por fractura de cadera. | |
CL2015002710A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso. | |
BR112018010211A2 (pt) | formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab | |
BR112017005693A2 (pt) | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. | |
BR112017001247A2 (pt) | divisores dinâmicos de juntas para janelas de aplicação | |
CL2016000009A1 (es) | Tratamiento de rosacea papulopustular con ivermectina. | |
CL2017000533A1 (es) | Pirrolopirimidinas para uso en la infección por el virus de la gripe | |
BR112016026993A2 (pt) | combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer | |
PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
BR112017001315A2 (pt) | fundamentos do dispositivo de computação modular | |
CL2017002521A1 (es) | Paginación de sistema de procesamiento de eventos. | |
CL2016000042A1 (es) | Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas. | |
CO2017003071A2 (es) | Sistema de fijación externo para un exoesqueleto ortopédico | |
AR103077A1 (es) | Método para la producción de un sistema de administración farmacéutica | |
AR098168A1 (es) | Formulación estable de insulina glulisina | |
BR112016024354A2 (pt) | gpio virtual híbrida | |
CL2016002338A1 (es) | Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática . | |
CL2015002180A1 (es) | Terapia de combinación para el tratamiento de neumonía nosocomial | |
BR112018013832A2 (pt) | formulação para a dissolução de ditiazina amorfa e método de uso | |
CL2016001746A1 (es) | Derivados de hidroxi formamida y sus usos | |
BR112015032526A2 (pt) | composições anticaspa e métodos de uso das mesmas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/07/2016, OBSERVADAS AS CONDICOES LEGAIS |